KPT‐330 and Y219 exert a synergistic antitumor effect in triple‐negative breast cancer through inhibiting NF‐κB signaling

Triple‐negative breast cancer (TNBC) is an aggressive breast cancer subtype, which has poor prognosis due to the lack of effective targeted drugs. KPT‐330, an inhibitor of the nuclear export protein CRM‐1, has been widely used in clinical medicine. Y219, a novel proteasome inhibitor designed by our...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Tiantian, Geng, Mengzhu, Bai, Enhe, Wang, Xueyuan, Miao, Hang, Chen, Zhimeng, Zhou, Hui, Wang, Jia, Shi, Jingmiao, Zhang, Yin, Lei, Meng, Zhu, Yongqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068319/
https://www.ncbi.nlm.nih.gov/pubmed/36847599
http://dx.doi.org/10.1002/2211-5463.13588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068319/
https://www.ncbi.nlm.nih.gov/pubmed/36847599
http://dx.doi.org/10.1002/2211-5463.13588

Ejemplares similares